Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human PrimatesGlobeNewsWire • 05/04/22
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 04/29/22
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 04/29/22
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease SummitGlobeNewsWire • 03/28/22
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEBGlobeNewsWire • 03/14/22
Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom FishingZacks Investment Research • 01/25/22
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and WarrantsGlobeNewsWire • 12/17/21
Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a TurnaroundZacks Investment Research • 11/19/21
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis BullosaGlobeNewsWire • 11/18/21
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM ConferenceGlobeNewsWire • 11/17/21
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/16/21
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific CongressesGlobeNewsWire • 10/13/21
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of QualityGlobeNewsWire • 10/12/21
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) FilingsGlobeNewsWire • 09/21/21
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene TherapyBenzinga • 07/28/21
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 07/28/21